Mostaghel et al., revealed that the treatment of enzalutamide, a potent AR antagonist, inhibited growth of various mantle cell lymphoma (MCL) cell lines examined, regardless of their gender origin (Granta, Jeko-1, RAMOS, Rec-1, Maver-1 cells). Here, AR is linked to mantle cell lymphoma.